List view / Grid view
Drug discovery research is funded primarily by government and by philanthropic groups. Later development is funded mainly by pharmaceutical companies.
A research project, based out of the University of Liverpool, which will bring together a multidisciplinary team of cancer surgeons, medical oncologists and scientists in Liverpool, has been given the go ahead thanks to £200,000 worth of grant funding.
Orion and Finland are both celebrating their centenaries in 2017.
Viking Therapeutics announced positive initial results from a proof-of-concept study of VK2809 in an in vivo model of glycogen storage disease Ia (GSD Ia).
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
The research group will explore novel approaches to vaccine development, focusing on the Zika virus.
A team of scientists from Austria, Australia, Denmark, England and the Czech Republic, led by Christian Gruber from the MedUni Vienna's Institute of Pharmacology, managed to isolate a neuropeptide from ants that is very similar to the human love hormone oxytocin, and the closely related hormone vasopressin.
Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017.
The USP9 gene has an indirect influence on the so-called tau protein, which is believed to play a significant role in the onset of Alzheimer’s disease.
Macrophage Pharma, a newly formed immune-oncology company, has successfully raised £9 million in a Series A equity financing round.
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
1 December 2016 | By Niamh Louise Marriott, Digital Editor
The funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies, with clinical development in 2017...
29 November 2016 | By Niamh Louise Marriott, Digital Editor
The Research Training Groups will receive funding of around €87 million for an initial period of four and a half years...
